Source-grounded facts extracted from Biomea Fusion, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Biomea Fusion, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.
“Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.”
Biomea Fusion, Inc. shareholders approved Election of two Class II directors at the 2026-06-10 meeting.
“Proposal 1 - Election of Directors The Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class II directors to hold office until the 2029 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.”
Biomea Fusion, Inc. reported first quarter ended March 31, 2026 results: net income net loss of $12.4 million.
“Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 2026”
Biomea Fusion, Inc. reported the year ended December 31, 2024 results: net income net loss of $138.4 million.
“The Company reported a net loss attributable to common stockholders of $61.8 million for the year ended December 31, 2025, which included $9.5 million of stock-based compensation, compared to a net loss of $138.4 million for the same period in 2024, which included $19.1 million of stock-based compensation.”
Biomea Fusion, Inc. reported the full year ended December 31, 2025 results: net income net loss of $61.8 million.
“Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the full year ended December 31, 2025 and provided a business update.”
Biomea Fusion, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)).
“March 27, 2025, Biomea Fusion, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c)(2)(A) due to the Company having only two members on its audit committee (the “Audit Committee”) of its Board of Directors of the Company (the “Board”) solely due to a vacancy resulting from Michael (Mick) J.M. Hitchcock, Ph.D.’s resignation from the Audit Committee in connection with his appointment as interim Chief Executive Officer of the Company effective March 25, 2025. The Company ha”
Rainer Erdtmann was appointed as Principal Financial Officer and Principal Accounting Officer at Biomea Fusion, Inc..
“Rainer (Ramses) Erdtmann, the Company’s President, Chief Operating Officer and a member of the Board, was appointed as the Company’s principal financial officer and principal accounting officer”
Michael J. M. Hitchcock was appointed as interim Chief Executive Officer at Biomea Fusion, Inc..
“Dr. Hitchcock, a member of the Board, was appointed as the Company’s interim Chief Executive Officer and principal executive officer”
Thomas Butler resigned as Director and Chairman of the Board at Biomea Fusion, Inc..
“On the Effective Date, Mr. Butler resigned as a director and Chairman of the Board”
Thomas Butler resigned as Chief Executive Officer at Biomea Fusion, Inc..
“The employment of Thomas Butler as Chief Executive Officer of the Company ended on March 25, 2025 (the “Effective Date”).”
Franco Valle resigned as Chief Financial Officer at Biomea Fusion, Inc..
“On February 24, 2025, Franco Valle resigned as the Chief Financial Officer (principal financial officer and principal accounting officer) of Biomea Fusion, Inc. (the “Company”), effective March 7, 2025.”
Biomea Fusion, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 2, 2024, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.”
Biomea Fusion, Inc. reported financial results for fourth quarter and full year 2023.
“Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights”
Biomea Fusion, Inc. reported financial results for the quarter ended September 30, 2023.
“On October 30, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.”
Biomea Fusion, Inc. reported financial results for the quarter ended June 30, 2023.
“On July 31, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023.”
Biomea Fusion, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm at the 2023-06-14 meeting.
“Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. Votes For Votes Against Abstentions 26,375,250 7,575 21,236 There were zero broker non-votes regarding this proposal.”
Biomea Fusion, Inc. shareholders approved Election of two Class II directors at the 2023-06-14 meeting.
“Proposal 1 - Election of Directors The Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class II directors to hold office until the 2026 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. Director Nominee Votes For Votes Withheld Rainer (Ramses) Erdtmann 16,369,686 5,798,793 Eric Aguiar, M.D. 16,248,905 5,919,574 There were 4,235,582 broker non-votes regarding this proposal.”
Biomea Fusion, Inc. reported financial results for the quarter ended March 31, 2023.
“On May 2, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023.”
Biomea Fusion, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Citigroup Global Markets Inc. valued at 5,000,000 shares of common stock at $30.00 per share, with option for additional 750,000 shares, agg (effective 2023-03-29).
“On March 29, 2023, Biomea Fusion, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreemen t ”) with J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein (the “Underwriters”) pursuant to which the Company agreed to issue and sell 5,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), to the Underwriters at a public offering price of $30.00 per share (the “Offering”). Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 750,000 shares of Common Stock at the same price per share (the “Option Shares”).”
Biomea Fusion, Inc. reported financial results for the quarter ended and year ended December 31, 2022.
“On March 28, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended and year ended December 31, 2022.”
Biomea Fusion, Inc. entered into Agreement with Piper Sandler & Co. valued at up to $100 million (effective 2022-11-25).
“On November 25, 2022, Biomea Fusion, Inc. (the “Company”) entered into an equity distribution agreement (the “Agreement”) with Piper Sandler & Co., as sales agent (the “Sales Agent”), with respect to an “at the market offering” program.”
Biomea Fusion, Inc. reported the quarter ended September 30, 2022 results: net income net loss attributable to common stockholders of $22.9 million.
“On November 7, 2022, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.”
Sunny Lee Ryan resigned as Executive Vice President of Finance at Biomea Fusion, Inc..
“On July 7, 2021, Sunny Lee Ryan, Executive Vice President of Finance of the Company, notified the Company of her decision to resign her position with Company, effective July 31, 2021”
Franco Valle was appointed as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at Biomea Fusion, Inc..
“On June 28, 2021, Biomea Fusion, Inc. Biomea Fusion, Inc. (“Biomea Fusion” or the “Company”) announced that Franco Valle, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will commence employment with the Company on July 26, 2021”
Sunny Lee Ryan resigned as Executive Vice President of Finance at Biomea Fusion, Inc..
“On July 7, 2021, Sunny Lee Ryan, Executive Vice President of Finance of the Company, notified the Company of her decision to resign her position with Company, effective July 31, 2021 (the “Effective Date”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.